150
Participants
Start Date
June 10, 2019
Primary Completion Date
July 16, 2022
Study Completion Date
July 16, 2022
Daratumumab
Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
All India Institute of Medical Sciences, New Delhi
Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh
Avron Hospitals Pvt. Ltd, Ahmedabad
Deenanath Mangeshkar Hospital and Research Centre, Pune
Noble Hospital Pvt Ltd, Pune
Shatabdi Super Speciality Hospital, Mumbai Naka
Apex Wellness Hospital, Nashik
Kingsway Hospital, Nagpur
Apollo Hospitals, Hyderabad
Basavatarakam Indo-American Hospital, Hyderabad
M S Ramaiah Medical College and Hospital, Bengaluru
Cytecare Hospitals Pvt. Ltd, Karnataka
Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry
Tata Medical Center, Kolkata
Apollo Hospitals, Bhubaneswar
Sparsh Hospitals & Critical Care (Pvt) Ltd, Bhubaneshwar
Lead Sponsor
Johnson & Johnson Private Limited
INDUSTRY